Hépato-Gastro & Oncologie Digestive
MENUAnti-TNF in IBD on mono- or combotherapy: when to stop or reduce the dose? Volume 30, issue 4, April 2023
Authors
CHU de Saint-Étienne, Service d’hépato-gastro-entérologie, Avenue Albert Raimond, 42270 Saint-Priest-en-Jarez
* Correspondance : X. Roblin
- Key words: Crohn’s disease biotherapy, remission, therapeutic de-escalation
- DOI : 10.1684/hpg.2023.2585
- Page(s) : 399-402
- Published in: 2023
Discontinuation of one of the infliximab-immunosuppressant combination therapy in patients in prolonged remission of Crohn’s disease is marked by symptomatic relapse when infliximab is discontinued but not when the immunosuppressant is discontinued. In patients in long-term remission on adalimumab, extending the frequency of injections is associated with a risk of relapse in one quarter of cases. These data suggest caution before considering de-escalation in patients who volunteer for prolonged remission.